tbuckley/cabot-search huggingface dataset:
PSYCHOLOGICAL INTERVENTIONS ASSOCIATED WITH INJURY PREVENTION: A SYSTEMATIC REVIEW
Authors: Adam Gledhill, Eliot Murray, Dale Forsdyke
Journal: British Journal of Sports Medicine (2017)

Background Sports injuries can have broad reaching health, performance, and financially-related problems for individual athletes and teams. There are widely recognized psychological injury risk factors therefore it follows that psychological skills training may be able to reduce the levels of injury risk. Objective To examine the relationship between psychological injury prevention interventions and injury risk reduction. Design Systematic review adopting PRISMA guidelines (PROSPERO reg. CRD42016035879). Setting Databases searched were CINAHL, MEDLINE, PsycARTICLES, PsycINFO, SPORTDiscus, PubMed and Science Direct. RCTs, non-RCTs that incorporated a comparison group, pre- and post- designs, and qualitative studies were eligible. Patients (or Participants) Twelve studies met the inclusion criteria. Studies included 1306 athletes (female n=520; male n=786) with an age range of 10–33 years and drawn from regional to international level sports. Interventions (or Assessment of Risk Factors) Varying psychological intervention strategies of varying modalities, intensities and volumes were adopted in the final studies. Main Outcome Measurements Mixed-methods Appraisal Tool (MMAT) was used to appraise study quality. Results Studies were appraised as having a moderate risk of bias in reporting. Eleven of the 12 included studies demonstrated a reduced injury risk as a result of the intervention. Five of the 12 included studies demonstrated a statistically significant difference. There is a bias towards the Stress Injury Model as the theoretical underpinning, contributing to a bias towards stress management studies. There is a dearth of literature which considers the role of psychological skills training in reducing non-stress related risk factors (e.g. imagery training to manage neuromuscular deficiency). Conclusions Evidence suggests psychological skills training can reduce the risk of sports injury occurrence, however this claim is drawn on research with a moderate risk of reporting bias.
Identification of Genomic Imbalances in AML with Complex Karyotype Using Matrix-Based Comparative Genomic Hybridization.
Authors: Frank G. Rucker, Carsten Schwanen, Daniel Lipka, Swen Wessendorf, Stefan Frohling, Hans Kestler, Peter Lichter, Martin Bentz, Konstanze Dohner, Hartmut Dohner
Journal: Blood (2004)
Pilot Study of a Wilms Tumor Protein (WT1) Heteroclitic Peptide Vaccine in Patients with Myeloid and Thoracic Neoplasms.
Authors: Peter G. Maslak, Lee Krug, Suzanne Chanel, Tao Dao, Leonard James, Leslie Tyson, Sara Bekele, David A. Scheinberg
Journal: Blood (2007)
A multi-level community engaged study exploring barriers to cancer care and clinical trial participation among black Bostonians.
Authors: Karen Marie Winkfield, Chidinma Osuagwu, Elizabeth Powell, Elmer Freeman, Linda Sprague-Martinez
Journal: Journal of Clinical Oncology (2015)

e17536 Background: In Boston, Massachusetts, disparities persist for Black residents across many chronic conditions including cancer. To assess perceptions in the Black community about cancer care, the Lazarex-MGH Cancer Care Equity Program partnered with the Center for Community Health Education Research and Services, Inc. to perform a cancer-focused community assessment. This exploratory community engaged research partnership sought to determine the perceived barriers to participation in clinical trials (CTs) and cancer care among Black Bostonians. Methods: As part of a 3-phase assessment, key informant interviews (n = 8) were conducted with health care providers, patient advocates and health educators focused on cancer care, grassroots coalition leaders, and Black cancer survivors. Audio files were transcribed and data was coded thematically using a consensus coding strategy to isolate themes pertinent to the study objective. Results: Barriers to cancer care and CTs were described by participants across individual, institutional, and community levels. At the individual level, barriers included poverty, education level, real or perceived experiences with racism, cultural disconnects, fear, life obligations, and mistrust. Grassroots and religious leaders were more likely to attribute mistrust to historical events while physicians practicing in the community believed that it was mistrust of institutions. Barriers at the institutional level were insurance, racism, and care coordination. At the community level, transportation was a reported barrier. Conclusions: Findings from this study are consistent with the literature indicating generational differences in how barriers to cancer care and CTs are perceived. Themes from this qualitative study will be used to develop a script for focus groups to be held in 3 different Boston neighborhoods with > 50% Black residents. Following completion of the assessment phase, data will be presented in a “town hall style meeting” to a broader group of community residents and stakeholders with the goal of developing a grassroots interventional strategy designed to a) reduce barriers to cancer care and b) increase awareness of cancer CTs.
Identification of Bipotent Basophil/Mast Cell Progenitors in Adult Murine Hematopoiesis.
Authors: Yojiro Arinobu, Hiromi Iwasaki, Michael F. Gurish, Shinichi Mizuno, Hirokazu Shigematsu, Hidetoshi Ozawa, Daniel G. Tenen, Frank K. Austen, Koichi Akashi
Journal: Blood (2005)
Comparison of SearchLight and Luminex multiplex assays: A case study of 27 cytokines in 156 melanoma blood serum samples.
Authors: Yan Lin, Lisa Butterfield, William A LaFramboise, Doug M Potter, Hui-Min Lin, Cindy Sander, John M. Kirkwood, Ahmad A. Tarhini
Journal: Journal of Clinical Oncology (2012)

79 Background: Searchlight and Luminex are two popular multiplex immunoassay platforms. Yet, very few studies have directly compared the performance of these two platforms on real clinical samples. Here we report a case study of 27 cytokines assayed by both platforms on 156 previously banked melanoma serum samples. Methods: Searchlight (Aushon) and Luminex (Invitrogene) assays were carried out according to protocols specified by the manufactures. Intra-experimental coefficients of variation (CV) of the intensities were calculated using the technical duplicates. The detection rate for each marker was calculated based on the cutoffs specified by the manufactures. Spearman’s correlation coefficient (r) was used to quantify the agreement of the measurements of each marker between the two platforms. Wilcoxon signed-rank tests were used to compare CVs and detection rates between the platforms. Results: We observed significantly higher intra-experimental CVs in the Searchlight data (median=8.9%, range=4.9%-11.9%) than in the Luminex data (median=4.1%, range=2%-7.5%, p&lt;0.0001). The CVs were not correlated between platforms (r=-0.08, p=0.69), suggesting that the CVs were not sample specific. We also observed a higher detection rate using the Searchlight platform (median=99%, range=26%-100%) than the Luminex platform (median=94%, range=18%-100%). However, the difference was not statistically significant (p=0.62). Spearman’s r for cytokine concentrations between platforms ranged from -0.13 to 0.86 (mean=0.44). The disagreement for 5 of the 6 cytokines with r&lt;=0.1 can be explained by their standard curves. Conclusions: In this case study of 156 samples, Luminex platform demonstrated significantly better reproducibility measured by CV and the Searchlight platform appeared to be more sensitive measured by the detection rate and the overall range of the measurements. The agreement between the two platforms ranges widely among the markers. Careful examination of the standard curves is critical to interpretation of the cytokine data. Assays of the cytokines by single analyte ELISA is ongoing.
440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm +) NSCLC: overall survival (OS) sdata from LUX-Lung 7 (LL7)
Authors: K. Park, E.H. Tan, L. Zhang, V. Hirsh, K. O’Byrne, M. Boyer, J.C.-H. Yang, T. Mok, K.H. Lee, S. Lu, Y. Shi, S.-W. Kim, J. Laskin, D.-W. Kim, S.A. Laurie, K. Kölbeck, J. Fan, N. Dodd, A. Märten, L. Paz-Ares
Journal: Annals of Oncology (2016)
Single Center Experience with Screening for JAK2 V617F, cMPL W515L, cMPL W515K, and JAK2 L611V Mutations in MPN. Rarity of JAK2 L611V Does Not Justify Its Routine Screening
Authors: Soo Jin Kim, Sabina Swierczek, Jonathan Schumacher, Todd W. Kelley, Sherrie L. Perkins, Josef T. Prchal
Journal: Blood (2011)
Changes in Medicaid reimbursements for cancer screening: Keeping pace with inflation?
Authors: M. T. Halpern, S. G. Haber, F. K. Tangka, D. H. Howard, L. C. Richardson, S. A. Sabatino, S. Sujha
Journal: Journal of Clinical Oncology (2011)

6043 Background: Uninsured individuals and Medicaid enrollees are more likely to present with advanced stage cancers at diagnosis. Increased access to cancer screening may aid in early diagnosis for these populations. However, while Medicaid programs cover a broad range of cancer screening services, anecdotal reports suggest that Medicaid reimbursements do not keep pace with inflation. This study assessed annual changes in Medicaid reimbursements for cancer screening services. Methods: We analyzed all Medicaid outpatient claims from four states (GA, IL, LO, ME) using the four most recent years of available data at the time of the study (2000-2003). Claims for screening tests for breast cancer (mammography), cervical cancer (Pap test), colorectal cancer (barium enema, flexible sigmoidoscopy, colonoscopy, and FOBT), and prostate cancer (PSA) as well as for physician office visits were identified using CPT codes. Dual Medicare-Medicaid enrollees were excluded. Average reimbursement rates were assessed each year and adjusted for inflation using the medical care component of the Consumer Price Index from the US Bureau of Labor Statistics. Results: Adjusting for inflation, Medicaid reimbursement for all colorectal cancer screening tests in each of the four states decreased from 2000 to 2003. Decreases in colonoscopy reimbursements over these four years ranged from approximately $11 (3.8%) in Louisiana to almost $45 (17.3%) in Illinois. PSA reimbursements also decreased over time in all four states, ranging from 12.2% to 19.2%. Mammography reimbursements increased by almost 5% in Georgia (from $29.62 to $31.00) but deceased in the other three states including a decrease of over 40% in Maine (from $22.78 to $13.00). Average reimbursements for physician office visits increased in Georgia (9.1%) and Louisiana (5.3%), but decreased in Illinois and Louisiana (both 12.2%). Conclusions: Our results indicate that Medicaid reimbursements for a number of cancer screening services did not keep pace with inflation over time among a sample of four states. This may restrict the access of Medicaid enrollees to critical screening services and thus limit access to care and improved health care outcomes among low-income underserved populations.
Long Term Molecular Remissions after Autologous Haematopoietic Stem Cell Transplant in Follicular Lymphoma.
Authors: Séverine Lissandre, Patrick Vourch, Isabelle Desbois, Lotfi Benboubker, Caroline Dartigeas, Martine Delain, Delphine Senecal, Philippe Colombat, Emmanuel Gyan
Journal: Blood (2008)
Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T).
Authors: Jonathan S. Cebon, Keith Flaherty, Jeffrey S. Weber, Kevin Kim, Jeffrey R. Infante, Adil Daud, Omid Hamid, Richard Kefford, Lynn Mara Schuchter, Jeffrey Alan Sosman, Mario Sznol, William Howard Sharfman, Rene Gonzalez, Miles Cameron Andrews, Roxana Stefania Dronca, Georgina Long, Shonda M Little, Peng Sun, Kiran Patel, Robert R. McWilliams
Journal: Journal of Clinical Oncology (2013)

9016 Background: The MAP kinase (MAPK) pathway is of critical importance for keratinocyte proliferation and maturation and is essential for epidermal homeostasis. Occurrence of hyperproliferative skin lesions including keratoacanthomas (KA) and cuSCC are considered a class effect of BRAFi [Anforth 2012, Chu 2012, Mattei 2012]. These effects, as well as promotion of pre-existing RAS-driven malignancies, may be caused by paradoxical activation of the MAPK pathway downstream of BRAF in wild-type BRAF cells. As MEK inhibition blocks downstream MAPK signaling, it was hypothesized that addition of a MEKi to a BRAFi would abrogate these effects [Su, 2012]. Methods: This 4-part phase I/II study enrolled 365 BRAF V600E/K mutated MM pts in Parts B-D. In part C, 162 pts (BRAFi and MEKi treatment-naïve, ≥ 18 yrs; ECOG PS &lt;2; RECIST measurable disease) were randomized to D monotherapy 150mg BID (D mono) vs. the combination of D (150 mg BID) and T (1 mg or 2 mg QD). Primary endpoints included safety and efficacy. Occurrence of cuSCC (including KA) across three arms in Part C and secondary malignancies with D+T across all Parts are provided below. Results: The difference in incidence of cuSCC between D mono and the D+T (150/1) was statistically significant, whereas the difference in incidence between D mono and D+T (150/2) was not. The median time to onset of cuSCC was 30 days in D mono compared to 282 and 152 days with D+T (150/1 and 150/2, respectively). Of 365 pts who received D+T, 2 (&lt;1%) cases of new cancers (colorectal and gliobastoma) and 2 (&lt;1%) cases of new primary malignant melanoma were reported. Conclusions: These data support the experimental hypothesis that the occurrence of cuSCC (including KA) can be substantially reduced and delayed by the addition of a MEKi to BRAFi therapy. Clinical trial information: NCT01072175. [Table: see text]
The Genotype of the Donor for the Polymorphism A7488G of the IL-17 Gene Influences relapse and survival After HLA-Identical Related Stem Cell Transplantation.
Authors: C. Martínez-Laperche, V. Noriega, Adela Herraiz, A. Bosh, V. Guillem, Jose B Nieto, M. González, Rafael De La Camara, S. Brunet, A. Jimenez-Velasco, Ildefonso Espigado, Juan Carlos Vallejo Llamas, Antonia Sampol, David Serrano, Jorge Gayoso, Pascual Balsalobre, Carlos Solano, David Gallardo, Jose Luis Diez-Martín
Journal: Blood (2010)
Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence.
Authors: Anamaria Crisan, Mercedeh Ghadessi, Christine Buerki, Ismael A. Vergara, Darby J. S. Thompson, Nicholas Erho, Thomas Sierocinski, Zaid Haddad, Benedikt Zimmermann, Worlanyo Sosu-Sedzorme, Sebastian Harko, Peter C. Black, Elai Davicioni, Robert B. Jenkins
Journal: Journal of Clinical Oncology (2012)

90 Background: Biochemical recurrence (BCR) may be an indicator of metastatic prostate cancer; however, it isn't specific enough to differentiate patients who will experience rapid onset of metastases from those who do not. Such lack of specificity leads to overtreatment of men who will likely never experience metastatic disease in their lifetime. We hypothesize that genomic biomarkers, detectable in primary tumor tissue, may better identify rapidly progressing metastatic prostate cancer. Methods: FFPE prostatectomy specimens (n = 309) from the Mayo Clinic tumor registry were profiled using a high-density expression array. Patients were retrospectively classified into three outcome groups: NED (no evidence of disease recurrence); BCR-only (patients that experienced BCR but no metastatic progression); and MET (metastatic disease confirmed by positive CT or bone scans) and were matched on several criteria for analysis . Uni- and multi-variable analyses between outcome groups were used to analyze clinical and genomic variables (adjusting for adjuvant hormone therapy as a confounding factor). Results: Median follow-up was 16.8 years and MET patients were diagnosed a mean of 3.1 years following BCR. Univariable and multivariable analysis of clinical variables failed to show statistically significant differences between NED and BCR-only outcome groups. Differential expression analysis between NED and BCR-only groups showed no significant differences after false discovery correction. Conversely, 6,277 and 52,020 biomarkers were differentially expressed between MET and the BCR-only and NED groups, respectively. Conclusions: Considering the clinical and genomic results together, patients who experienced rapid metastatic disease were significantly different from both the NED and BCR-only groups. However, no significant differences were identified between the BCR-only and NED outcome groups. These results imply that BCR is not a good surrogate for men who are likely to experience rapid onset of metastatic disease and lethal prostate cancer.
Peripheral Blood (PB) CD56bright and CD56dim Do Not Exhibit Differences in NKR Expression Compared to Their Cord Blood (CB) Counterparts: CB CD56dim May Represent an Intermediary between CB CD56bright and PB CD56dim.
Authors: Evan Shereck, Prakash Satwani, Carmella van de Ven, Janet Ayello, Ronald J. Wapner, Nancy Day, Hong Jiang, Mitchell S. Cairo
Journal: Blood (2006)
EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.
Authors: Deirdre O’Mahony, John C. Morris, Maryalice Stetler-Stevenson, Helen Matthews, Stefania Pittaluga, Paul Albert, Karen Kaucic, Luz Hammershaimb, Thomas A. Waldmann, John E. Janik
Journal: Blood (2007)
RARE-55. LANGERHAN’S CELL HISTIOCYTOSIS (LCH) ASSOCIATED WITH LEPTOMENINGEAL ACUTE MYELOID LEUKEMIA (AML): A CASE REPORT
Authors: Christopher Trevino, Alissa Thomas, Marie Wood, Gary Landrigan, John Lunde, Katherine Devitt, Himani Singh
Journal: Neuro-Oncology (2016)

LCH is a rare hematopoietic malignancy due to dendritic cell clonal proliferation, which commonly presents as sinusitis. Between 6 and 25% of LCH cases involve the central nervous system (CNS). LCH is rarely associated with other hematologic malignancies, including AML. We describe a 59-year-old patient with LCH of the right frontal sinus metastatic to regional lymph nodes and colon who presented with acute meningoencephalitis and was found to have AML isolated to the CNS. The patient initially presented with antibiotic-refractory recurrent sinusitis and was diagnosed with LCH following sinus biopsy. He was treated with 2 cycles of cytarabine (100 mg/m2 daily x 5 days) but progressed with metastatic disease to lymph nodes and colon (biopsy confirmed). He received 2 cycles of clofarabine with partial response on CT/PET, which was complicated by neutropenia (WBC 0.95, ANC 0.47). He was admitted to the hospital with altered mental status, generalized weakness, and multiple cranial neuropathies. Work up revealed a right frontal dural based mass and cerebrospinal fluid analysis significant for protein >550 mg/dL, glucose <20 mg/dL, and 2105 nucleated cells/mcL. CSF cultures were negative and he did not respond to empiric antibiotics. CSF flow cytometry was consistent with AML, monocytic subtype. Analysis of peripheral blood was notable for pancytopenia without blasts or clonal population of cells. Due to pancytopenia and poor performance status the patient was unable to receive chemotherapy and died on hospice shortly after diagnosis. To the best of our knowledge, this is the only reported case of central nervous systemic AML associated with LCH.
Bridging the gap: The design of a survivorship curriculum for interspecialty collaboration.
Authors: Emmanuel Ozokwelu, Jeffrey James Sisler, Jonathan Sussman, Som Mukherjee, Stephanie Mowat, Anita Ens, Cheryl Moser, Gerald Konrad, Joel Roger Gingerich
Journal: Journal of Clinical Oncology (2016)

13 Background: Interspecialty learning between trainees from different postgraduate training programs is unusual in Canada. Primary care providers (PCPs) have an increasing role in the provision of survivorship care in collaboration with cancer specialists (ONC), but coordination of care is often lacking and avenues for joint learning and interaction among these physicians are limited during residency. We are piloting a learning suite (LS) for PCP and ONC trainees in MB, ON &amp; BC as part of a pan-Canadian study on integration of care between primary and cancer specialty care. Methods: Using Kern’s Six-Step Approach to Curriculum Design, a national team of experts conducted surveys and focus groups with postgraduate program directors, cancer survivors, and trainees. We set learning objectives as informed by the needs assessment and used constructive alignment to build the curriculum in a blended learning format: online, workshop and clinical. We are assessing inter-disciplinary learning outcomes comparing pre and post results on a modified Readiness for Interprofessional Learning Scale (M-RIPLS) in three pilot sites in 2015 with about 40 family medicine and oncology trainees. Results: Learning materials have been developed for a mixed audience of trainees. The interactive, one hour online session addresses cancer epidemiology, the domains of survivorship care, and specific issues in follow-up care for three cancer types, as well as province-specific survivorship initiatives. This is followed by a two hour, case-based learning workshop that focuses on collaboration and shared care. A clinical experience in cancer follow-up clinics concludes the LS. In PCP training sites without a nearby cancer centre, trainees are able to review videos of actual transitional appointments and follow-up clinics and of the cancer centre/oncologist perspective on shared care. Pilots are ongoing in 2015 with national rollout in 2016. Conclusions: We expect that learning together in residency will impact on attitudes towards interspecialty collaboration in the care of cancer survivors. This interspecialty, blended learning curriculum will enhance the place of survivorship training in the postgraduate education of Canadian physicians.
EXTH-04. PAM-OBG: A MAOB SENSITIVE PRODRUG THAT INHIBITS GLIOMAL MGMT
Authors: Martyn Sharpe, David Baskin
Journal: Neuro-Oncology (2016)

Current treatment modalities for glioblastoma multiforme (GBM) are palliative rather than curative. TMZ is an alkylating agent and its cytotoxicity is a function of its ability to methylate DNA; however, this damage can be repaired by O6-methylguanine DNA methyltransferase (MGMT). MGMT can be targeted by pseudo-substrates, with O6-benzylguanine (OBG) being the best known and characterized. OBG has been used with alkylating agents to overcome chemotherapeutic resistance. Unfortunately OBG inhibits DNA repair systemically, causing hypersensitivity to alkylating agents globally. Adequate doses cannot be given because of bone marrow toxicity. GBM upregulation of MAOB almost 10 fold provides a new key target for novel chemotherapeutics. The rationale for the development of chemotherapeutic prodrugs relies upon a maturation process, prodrug→mature drug, where maturation is higher in target cells compared to non-cancerous tissues. We have developed an MAOB oxidizable propylamine carbamate of OBG (PAM-OBG) that will not react with MGMT until it binds to MAOB, and is converted into OBG. PAM-OBG is a MAOB sensitive version of OBG that is not an MGMT inhibitor prior to MAOB catalysis. Thus, only after binding to MAOB is OBG released, which delivers the active compound primarily to tumor cells. In a primary GBM intracranial mouse model animals treated with vehicle had an average survival of 17.3 ± 1.6 days. Life extension with monotherapies was modest; 3x5mg/kg PAM-OBG=5.3 days, 3x15mg/kg BCNU=7.24 days and 3x15mg/kg CCNU=18.15 days. Combined PAM-OBG/BCNU extends life by 33.8 days and using PAM-OBG/CCNU life extension is at least 63 days. Selective targeting of MAOB with no prodrug toxicity until conversion to OBG produces striking results, and may be a powerful adjunct to current treatment protocols. The lack of toxicity using selective targeting allows for a sufficient dose yielding marked enhancement of chemotherapy, and effects in animal studies are striking. If effective in humans, PAM-OBG may change the course of care for patients with glioblastoma.